Oppenheimer raised the firm’s price target on Fusion Pharmaceuticals to $15 from $13 and keeps an Outperform rating on the shares. Top-pick Fusion on Thursday provided a detailed portfolio and corporate update, highlighting its recent alignment with the FDA on a registrational development plan for FPI-2265 in mCRPC, the analyst tells investors in a research note. The company also updated its cash guidance as sufficient to support operations into 4Q25 based on recent ATM proceeds, the firm notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN:
- RayzeBio downgraded to Hold from Buy at Truist
- Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
- Recent M&A activity bodes well for Fusion Pharmaceuticals, says Oppenheimer
- Fusion Pharmaceuticals upgraded at Raymond James amid radiopharma M&A
- Fusion Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
